Ardent Health, Inc. Faces Class Action for Securities Fraud After 33% Stock Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Source: Globenewswire
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a 33% stock drop from $14.05 to $9.30 on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health did not primarily rely on 'detailed reviews of historical collections' for assessing accounts receivable collectability, instead using a 180-day cliff, which inflated reported receivables.
- Revenue Loss: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease due to 'hindsight evaluations of historical collection trends' and increased professional liability reserves by $54 million, raising investor concerns.
- Legal Options: Investors are encouraged to apply to lead the case by March 9, 2026, with BFA offering representation on a contingency fee basis, ensuring shareholders incur no litigation costs.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.73 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 8.630
Low
10.00
Averages
13.73
High
17.00
Current: 8.630
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
